CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider.You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

Pfizer to buy Array BioPharma in $11.4 billion deal

The largest US drugmaker acquires the cancer drugmaker in one of the biggest healthcare deals of the year.

Pfizer has purchased Array BioPharma in a deal worth $11.4 billion that will be financed by cash and debt. Array BioPharma’s share price soared 56% after the acquisition.

Pfizer’s Array BioPharma acquisition details

Pfizer is the largest drugmaker in the US and Array BioPharma is a biopharmaceutical startup that is developing cancer treatments that target mutations found in a wide variety of tumors. Pfizer bought Array BioPharma to expand its cancer drug portfolio.

Two of Array BioPharma’s medications, Braftovi and Mektovi, have been approved by the US Food and Drug Administration (FDA) to treat late-stage melanoma. Pfizer will get royalties from future Braftovi and Mektovi revenue as part of the deal.

Pfizer and Array BioPharma comment on acquisition

Pfizer chief executive officer (CEO), Albert Bourla, explained the benefits of the acquisition of Array BioPharma.

‘The proposed acquisition of Array strengthens our innovative biopharmaceutical business, is expected to enhance its long-term growth trajectory, and sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside Pfizer's existing expertise in breast and prostate cancers,’ said Bourla in a statement.

‘[The deal] reinforces our commitment to deploy our capital to bring breakthroughs that change patients' lives,’ added Bourla.

Ron Squarer, Array’s chief executive officer (CEO), also touted the deal with Pfizer.

‘We are incredibly proud that Pfizer has recognised the value Array has brought to patients and our remarkable legacy discovering and advancing molecules with great potential to impact and extend the lives of patients in critical need,’ said Squarer.

The Pfizer acquisition of Array BioPharma is expected to be completed in late 2019.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Monday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.